Literature DB >> 9728551

Cysteine proteases of Trichomonas vaginalis degrade secretory leukocyte protease inhibitor.

D Draper1, W Donohoe, L Mortimer, R P Heine.   

Abstract

Sexually transmitted diseases, including trichomoniasis, are risk factors for acquisition of human immunodeficiency virus (HIV) infection. Enhancement mechanisms are unknown. Secretory leukocyte protease inhibitor (SLPI) from saliva appears to prevent transmission of HIV through inhibition of virus entry into monocytic cells in vitro. This study was undertaken to determine if secreted cysteine proteases of Trichomonas vaginalis degrade SLPI and render it nonfunctional. It was determined if SLPI levels were decreased in vaginal fluids from pregnant women infected with T. vaginalis. Isolated proteases were incubated with recombinant human SLPI, and the degradation was followed by Western analysis with SLPI antiserum. SLPI levels were measured by ELISA in vaginal fluids from women infected with T. vaginalis and uninfected controls. Cysteine proteases cleaved SLPI and rendered it nonfunctional. Median levels of SLPI from infected patients were 26% of those of controls (P <.005). The degradation of SLPI in association with trichomonal infection may increase the risk of HIV acquisition.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9728551     DOI: 10.1086/515366

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  30 in total

1.  Lower Genital Tract Infections and HIV in Women.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-12       Impact factor: 3.725

Review 2.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

3.  Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infection.

Authors:  Richard M Novak; Betty A Donoval; Parrie J Graham; Lucy A Boksa; Gregory Spear; Ronald C Hershow; Hua Yun Chen; Alan Landay
Journal:  Clin Vaccine Immunol       Date:  2007-08-01

Review 4.  Trichomoniasis.

Authors:  Jane R Schwebke; Donald Burgess
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

5.  Secretory leukocyte protease inhibitor binds to Neisseria gonorrhoeae outer membrane opacity protein and is bactericidal.

Authors:  Morris D Cooper; Melissa H Roberts; Ona L Barauskas; Gary A Jarvis
Journal:  Am J Reprod Immunol       Date:  2012-04-26       Impact factor: 3.886

6.  Trichomonas vaginalis infection: can we afford to do nothing?

Authors:  R Scott McClelland
Journal:  J Infect Dis       Date:  2008-02-15       Impact factor: 5.226

Review 7.  Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies.

Authors:  Julius Atashili; Charles Poole; Peter M Ndumbe; Adaora A Adimora; Jennifer S Smith
Journal:  AIDS       Date:  2008-07-31       Impact factor: 4.177

Review 8.  Trichomonas vaginalis vaginitis in obstetrics and gynecology practice: new concepts and controversies.

Authors:  Jenell S Coleman; Charlotte A Gaydos; Frank Witter
Journal:  Obstet Gynecol Surv       Date:  2013-01       Impact factor: 2.347

9.  Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism.

Authors:  Esra Fakioglu; Sarah S Wilson; Pedro M M Mesquita; Ehsan Hazrati; Natalia Cheshenko; John A Blaho; Betsy C Herold
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

Review 10.  Trichomonas vaginalis, HIV, and African-Americans.

Authors:  F Sorvillo; L Smith; P Kerndt; L Ash
Journal:  Emerg Infect Dis       Date:  2001 Nov-Dec       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.